What is the clinical evidence from this study?

Study design: Review. Population: Left ventricular hypertrophy. Intervention: Antihypertensive therapy (calcium antagonists, ACE inhibitors, beta-blockers).

What question did this study set out to answer?

To assess the effectiveness of various management strategies for left ventricular hypertrophy (LVH).

April 20, 2026

Management of the patient with left ventricular hypertrophy

Key Result

Antihypertensive drug treatment effectively reduces left ventricular hypertrophy, although regression may not be achievable in over 50% of patients.

Key Points

To assess the effectiveness of various management strategies for left ventricular hypertrophy (LVH).
Patients identified through echocardiography for risk assessment.
Treatment options included calcium antagonists, ACE inhibitors, and beta-blockers.
Focus on monitoring blood pressure during antihypertensive therapy.
Effective drug treatments demonstrated reduction in LVH and management of associated dysfunction.
No evidence of improvement in myocardial ischaemia from treatments.
Regression of LVH is achievable in less than 50% of patients.

Structured PICO

Does antihypertensive drug treatment reduce left ventricular hypertrophy and associated complications in patients with LVH?

Population

Patients with left ventricular hypertrophy (LVH) identified by echocardiography

Intervention

Antihypertensive drug treatment (calcium antagonists, angiotensin converting enzyme inhibitors, and beta-blockers) and non-pharmacological treatment

Outcome

Left ventricular hypertrophy regressionsurrogate

Antihypertensive therapy, particularly with calcium antagonists, ACE inhibitors, and beta-blockers, is effective in reducing left ventricular hypertrophy and controlling associated complications, which may decrease cardiovascular morbidity and mortality.

Limitations

Regression may not be achievable in over 50% of patients
Not possible to identify patients in whom regression is likely
No evidence of beneficial effect on myocardial ischaemia

Abstract

The management of left ventricular hypertrophy (LVH) presupposes that the patient is identified by echocardiography and is carefully evaluated for risk stratification, taking into consideration possible associated complications. The role of non-pharmacological treatment is limited, except in obese patients. Drug treatment, especially using calcium antagonists, angiotensin converting enzyme inhibitors and beta-blockers, has proved to be effective in reducing LVH. These drugs are also effective in controlling, if not reversing, the associated pathophysiological changes and complications, such as impaired systolic and diastolic function, and ventricular arrhythmias. There is, however, no evidence of any beneficial effect on myocardial ischaemia. The desirable goal is LVH regression, but it may not be achievable in over 50% of patients, and it is not possible to identify patients in whom regression is likely. Regression, or control of each sequelae, could prevent sudden death, the evolution of hypertensive heart disease leading to heart failure and, probably, myocardial infarction. Patients must be followed carefully during and, particularly, at the beginning of the antihypertensive therapy which has to be gradually introduced. At best, blood pressure must be reduced while avoiding hypotension. The strategy of antihypertensive treatment has to be reconsidered on the basis of the presence of LVH and could lead to decreased cardiovascular morbidity and mortality of patients with LVH.